Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943716 | 0.87 | DGAT1 (0.37) | CYP2C19KMT2A | |
| SCHEMBL7894866 | 0.84 | CYP2C9 (0.36) | TSHRCYP2C19CYP2D6HIF1AELANE | |
| Hydrogen Peroxide SCHEMBL28451976 | 0.80 | PRKCA (0.42) | CYP2C19ELANEALDH1A1KMT2A | |
| Carbamic Acid SCHEMBL29228025 | 0.79 | PRKCA (0.38) | CYP2C19ELANEKMT2A | |
| SCHEMBL1299895 | 0.78 | CYP4F2 (0.44) | TSHRCYP2C19CYP2D6HIF1AALDH1A1 | |
| SCHEMBL2597349 | 0.77 | DGAT1 (0.56) | CYP2C19KMT2A | |
| SCHEMBL1785142 | 0.77 | CYP2C19 (0.36) | CYP2C19KMT2A | |
| SCHEMBL733594 | 0.77 | PRKCA (0.43) | CYP2C19ELANEALDH1A1KMT2A | |
| Lithium SCHEMBL30945444 | 0.76 | CYP4F2 (0.42) | TSHRCYP2C19CYP2D6HIF1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11066122 | 0.76 | CYP4F2 (0.42) | TSHRCYP2C19CYP2D6HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111448182-A | Aztreonam derivative and application thereof | 阿里萨制药有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2571862-A1 | PRODRUG OF TRIAZOLONE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2011145747-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011145747-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-24 | — | — | WO | disclosed |
| US-6331620-B1 | AS POLYMERIZATION CATALYSTS FOR PRODUCING STEREOSPECIFIC HOMOPOLYMER OR COPOLYMER OF ALPHA-OLEFINS | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2001-12-18 | — | — | US | disclosed |
| US-5270401-A | Plastics composition based on a thermoplastic blend of a polyamide and a polyester | DSM N.V. (NL) | 1993-12-14 | — | — | US | disclosed |
| EP-0481556-A1 | Plastics composition based on a thermoplastic blend of a polyamide and a polyester | DSM N.V. (NL) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | F7, TFPI, TFPI2 | TSHR 1050/4885CYP2C19 17/4885CYP2D6 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.